Today the Washington Post has an article – "FDA Commissioner Faces Formidable To Do List" that outlines the many challenges that Dr. Margaret Hamburg and Dr. Joshua Sharfstein face as they get settled into their new jobs. This includes the usual suspects that have been well documented and bemoaned these past eight years – politics trumping science (Plan B fiasco), enormous food recalls (frankly not the fault of the agency), whistle blowing employees, and the growth of interaction brought on by the global economy without a corresponding change in agency approaches and resources. All vexing and huge problems.
About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date